How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
In 2022, 1 in 8 people in the world were living with obesity, and lifestyle interventions that include diet, exercise, and behavioral modification have been the foundation for management of obesity. Recently, pharmacologic therapies have been developed for management of obesity, the newest of these being glucagon-like peptide 1 receptor agonists. With the development of new pharmacologic options, the American Gastroenterological Association developed a guideline in 2022 to provide evidence-based recommendations for the pharmacologic management of obesity in adults and recommended, for adults with obesity or overweight with weight-related complications who have had an inadequate response to lifestyle interventions, adding pharmacologic agents to lifestyle interventions over continuing lifestyle interventions alone. In this article, 2 experts review the available evidence to answer the following questions: How effective are lifestyle interventions for the treatment of obesity? How effective are pharmacologic interventions for the treatment of obesity? Given these options, how do you engage in a shared decision-making discussion to develop a mutually agreed-on treatment plan?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This combined strategy leverages the benefits of medication and surgery alongside personalized lifestyle interventions to achieve superior health outcomes [323,324].”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [323]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Recently FDA-approved tirzepa-tide has dual-hormone agonistic activity at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor (GIP/GLP-1RA) and produces weight loss up to 20% at the highest dose (10 mg subcutaneously) (19, 20).”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“…of organs affected and modes of action may explain the extent of bene fi ts found beyond management of obesity, including treatment of metabolic dysfunction – associated stea-totic liver disease (MASLD; formerly called nonalcoholic fatty liver disease) and improvement in cardiovascular outcomes (5).”
Thompson, P. D., Buchner, D., Piña, I. L., Balady, G. J., Williams, M. A., Marcus, B. H., Berra, K., Blair, S. N., Costa, F., Franklin, B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000075572.40158.77 · Cited by 2,132
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“The GLP-1RAs have various metabolic effects, including glucose-dependent stimulation of insulin secretion, delayed gastric emptying, and inhibition of food intake (4).”
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Messier, S. P., Loeser, R. F., Miller, G. D., Morgan, T. M., Rejeski, W. J., Sevick, M. A., Ettinger, W. H., Pahor, M., & Williamson, J. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20256 · Cited by 1,065 · cited 1×
“Additional health bene fi ts included improvements in obstructive sleep apnea (9), knee osteoarthritis (10, 11), MASLD (12), quality of life, and depression (13).”
Lichtenstein, A. H., Appel, L. J., Vadiveloo, M., Hu, F. B., Kris-Etherton, P. M., Rebholz, C. M., Sacks, F. M., Thorndike, A. N., Van Horn, L., Wylie-Rosett, J., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001031 · Cited by 1,065
Self-citationDose Response Between Physical Activity and Risk of Coronary Heart Disease: A Meta-Analysis
Sattelmair, J., Pertman, J., Ding, E. L., Kohl, H. W., Haskell, W., & Lee, I.-M. (2011) · Circulation · doi:10.1161/circulationaha.110.010710 · Cited by 1,052 · cited 1×
“There is a dose effect on cardiovascular outcomes, even when recommended activity guidelines are not achieved (34, 35).”
Messier, S. P., Mihalko, S. L., Legault, C., Miller, G. D., Nicklas, B. J., DeVita, P., Beavers, D. P., Hunter, D. J., Lyles, M. F., Eckstein, F., et al. (2013) · JAMA · doi:10.1001/jama.2013.277669 · Cited by 873
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816 · cited 1×
“The strongest predictors of weight loss maintenance include self-monitoring, increased physical activity, and adherence to eating behaviors, such as portion control and reduced energy intake (15, 16).”
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Self-citationUS Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Grossman, D. C., et al. (2018) · JAMA · doi:10.1001/jama.2018.13022 · Cited by 563
Foster, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.266 · Cited by 538
One-year weight losses in the Look AHEAD study: factors associated with success
Wadden, T. A., West, D. S., Neiberg, R. H., Wing, R. R., Ryan, D. H., Johnson, K. C., Foreyt, J. P., Hill, J. O., Trence, D. L., Vitolins, M. Z., et al. (2009) · Obesity · doi:10.1038/oby.2008.637 · Cited by 525
Lobelo, F., Rohm Young, D., Sallis, R., Garber, M. D., Billinger, S. A., Duperly, J., Hutber, A., Pate, R. R., Thomas, R. J., Widlansky, M. E., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000559 · Cited by 402
Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events
Stens, N. A., Bakker, E. A., Mañas, A., Buffart, L. M., Ortega, F. B., Lee, D.-C., Thompson, P. D., Thijssen, D. H. J., & Eijsvogels, T. M. H. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.029 · Cited by 343
Determinants of weight loss maintenance: a systematic review
Varkevisser, R. D. M., van Stralen, M. M., Kroeze, W., Ket, J. C. F., & Steenhuis, I. H. M. (2019) · Obesity Reviews · doi:10.1111/obr.12772 · Cited by 295
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Effective strategies in ending weight stigma in healthcare
Talumaa, B., Brown, A., Batterham, R. L., & Kalea, A. Z. (2022) · Obesity Reviews · doi:10.1111/obr.13494 · Cited by 250 · cited 1×
“These experiences of weight bias can further emotional eating and stress, creating more barriers to health and weight loss (41).”
Williamson, D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.544 · Cited by 244
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03015-5 · Cited by 238 · cited 1×
“In people with obesity and cardiovascular disease, sem-aglutide decreases the risk for death from cardiovascular causes (3), nonfatal myocardial infarction, or nonfatal stroke (5) and it may also decrease blood pressure (42) and improve kidney function (43).”
Accelerometer-derived "weekend warrior" physical activity and incident cardiovascular disease
Khurshid, S., Al-Alusi, M. A., Churchill, T. W., Guseh, J. S., & Ellinor, P. T. (2023) · JAMA · doi:10.1001/jama.2023.10875 · Cited by 204
Nutter, S., Eggerichs, L. A., Nagpal, T. S., Ramos Salas, X., Chin Chea, C., Saiful, S., Ralston, J., Barata‐Cavalcanti, O., Batz, C., Baur, L. A., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13642 · Cited by 184 · cited 1×
“Discussing obesity requires a patient-centered approach that avoids blame or shame, using nonstig-matizing language and focusing on overall health and well-being (26).”
Oussaada, S. M., van Galen, K. A., Cooiman, M. I., Kleinendorst, L., Hazebroek, E. J., van Haelst, M. M., ter Horst, K. W., & Serlie, M. J. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.012 · Cited by 180 · cited 1×
“When they lose weight, their hunger hormones (for example, ghrelin) increase, their satiety signals (for example, via leptin) are blunted, and metabolic adaptations lead to lower energy expenditure, which can all lead to weight plateaus and regain (40).”
Gardner, C. D., Vadiveloo, M. K., Petersen, K. S., Anderson, C. A. M., Springfield, S., Van Horn, L., Khera, A., Lamendola, C., Mayo, S. M., Joseph, J. J., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001146 · Cited by 172
Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1605 · Cited by 156 · cited 1×
“Metformin is also an excellent option, given that she has prediabetes; it can lead to clinically signi fi cant weight loss (52) and has been shown to decrease the risk for progression to type 2 diabetes (53).”
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126 · cited 1×
“In observational data, real-world adherence to GLP-1RAs prescribed for diabetes was 65% at 1 year and 30% at 2 years; adherence was highest among those with lowest insurance copays (23, 24).”
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity · doi:10.1002/oby.23673 · Cited by 124
Vadiveloo, M., Lichtenstein, A. H., Anderson, C., Aspry, K., Foraker, R., Griggs, S., Hayman, L. L., Johnston, E., Stone, N. J., Thorndike, A. N., et al. (2020) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000094 · Cited by 112
Self-citationNutrition Education in Medical School, Residency Training, and Practice
Devries, S. R., Willett, W. C., & Bonow, R. O. (2019) · JAMA · doi:10.1001/jama.2019.1581 · Cited by 108
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Systematic Review of Behavioral Weight Management Program MOVE! for Veterans
Maciejewski, M. L., Shepherd‐Banigan, M. E., Raffa, S. D., & Weidenbacher, H. J. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.01.029 · Cited by 71 · cited 1×
“Even when programs are available, free, and widely promoted (such as the MOVE! program through the Department of Veterans Affairs), only 3% to 50% of eligible patients attend 1 or more visits (38).”
Use and Misuse of BMI Categories
Flegal, K. M. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.550 · Cited by 71
Essien, U. R., Singh, B., Swabe, G., Johnson, A. E., Eberly, L. A., Wadhera, R. K., Breathett, K., Vaduganathan, M., & Magnani, J. W. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.16290 · Cited by 69 · cited 1×
“In observational data, real-world adherence to GLP-1RAs prescribed for diabetes was 65% at 1 year and 30% at 2 years; adherence was highest among those with lowest insurance copays (23, 24).”
Herbozo, S., Brown, K. L., Burke, N. L., & LaRose, J. G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00493-5 · Cited by 36 · cited 1×
“Clinicians should approach conversations with awareness of how racial, ethnic, and socioeconomic disparities and psychological factors (for example, depression [27]) impact obesity and treat-ment access.”
Atlas, S. J., Kim, K., Nhan, E., Touchette, D. R., Moradi, A., Agboola, F., Rind, D. M., Beaudoin, F. L., & Pearson, S. D. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.569 · Cited by 33
Kronsteiner-Gicevic, S., Tello, M., Lincoln, L. E., Kondo, J. K., Naidoo, U., Fung, T. T., Willett, W. C., & Thorndike, A. N. (2023) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2023.05.023 · Cited by 32
Self-citationWu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 30 · cited 1×
“In people with obesity and cardiovascular disease, sem-aglutide decreases the risk for death from cardiovascular causes (3), nonfatal myocardial infarction, or nonfatal stroke (5) and it may also decrease blood pressure (42) and improve kidney function (43).”
Alabduljabbar, K., Alsaqaaby, M., Neff, K. J., Crotty, M., & le Roux, C. W. (2023) · Endocrine · doi:10.1007/s12020-023-03534-0 · Cited by 16
Cited by
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“This combined strategy leverages the benefits of medication and surgery alongside personalized lifestyle interventions to achieve superior health outcomes [323,324].”
Wee, C. C., Arbaje, A. I., Bering, H., Blount, L. G., Joseph, J. J., Kahan, S. I., Apovian, C. M., & White-Faines, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00675 · Cited by 3
Metadata
- Authors
- Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- New York University (US)
- Harvard University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2024-10
- Volume
- 177
- Issue
- 10
- Pages
- 1415-1424
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4403177428
- Cited by
- 2
- References
- 49
- Citations by year
- 2025: 2
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, obesity pharmacotherapy, lifestyle intervention, GLP-1 receptor agonists, shared decision-making, treatment effectiveness, American Gastroenterological Association guidelines
- MeSH terms
- Decision Making, Shared, Adult, Humans, Life Style, Obesity, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.